Abstract:Currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common neurodegenerative disease resulting in personality changes, cognitive impairment, memory loss, and physical disability. Diagnosis of AD is often missed or delayed in clinical practice due to the fact that cognitive deterioration occurs already in the later stages of the disease. Thus, methods to improve early detection would provide opportunities for early treatment of disease. All FDA-approved PET imaging agents for Aβ plaques use short-lived radioisotopes such as 11C (t1/2 = 20.4 min) and 18F (t1/2 = 109.8 min), which limit their widespread use. Thus, a novel metal-based imaging agent for visualization of Aβ plaques is of interest, due to the simplicity of its synthesis and the longer lifetimes of its constituent isotopes. We have previously summarized a metal-containing drug for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer's disease. In this review, we have summarized a recent advance in design of Aβ-targeting bifunctional chelators for potential therapeutic and PET imaging applications, reported after our previous review.

Recent progress in the development of metal complexes as beta-amyloid imaging probes in the brain

Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain.

Metals in Imaging of Alzheimer’s Disease

Oligoethyleneoxy-Modified 99Mtc-Labeled Β-Amyloid Imaging Probes with Improved Brain Pharmacokinetics for Single-Photon Emission Computed Tomography.

Aβ-Targeting Bifunctional Chelators (BFCs) for Potential Therapeutic and PET Imaging Applications

Synthesis and biological evaluation of novel technetium-99m labeled phenylbenzoxazole derivatives as potential imaging probes for β-amyloid plaques in brain.

99Mtc-Labeled 2-Arylbenzothiazoles: Aβ Imaging Probes with Favorable Brain Pharmacokinetics for Single-Photon Emission Computed Tomography.

(99M)tc-Labeled Dibenzylideneacetone Derivatives As Potential SPECT Probes for in Vivo Imaging of Β-Amyloid Plaque.

99mTc- and Re-labeled 6-dialkylamino-2-naphthylethylidene derivatives as imaging probes for β-amyloid plaques.

Past And Recent Progress Of Molecular Imaging Probes For Beta-Amyloid Plaques In The Brain

2-Arylbenzothiazoles Labeled with [cpre/99mtc(co)3] and Evaluated As Β-Amyloid Imaging Probes.

2-Phenylbenzothiazole conjugated with cyclopentadienyl tricarbonyl [CpM(CO)3] (M = Re, (99m)Tc) complexes as potential imaging probes for β-amyloid plaques.

Novel ¹⁸F-labeled dibenzylideneacetone derivatives as potential positron emission tomography probes for in vivo imaging of β-amyloid plaques.

Metal complexes and their applications in bioassay, bio-imaging and protein staining

Compounds for Imaging Amyloid-Β Deposits in an Alzheimer’s Brain: a Patent Review

(99M)tc-Labeled-2-arylbenzoxazole Derivatives As Potential Aβ Imaging Probes for Single-Photon Emission Computed Tomography.

Radiolabeled Bioactive Benzoheterocycles for Imaging Beta-Amyloid Plaques in Alzheimer'S Disease

A Beta-Binding Molecules: Possible Application As Imaging Probes And As Anti-Aggregation Agents

Recent Advances in Fabricating the Multifunctional A beta Small Organic Molecule Probes for Theranostic Application

Novel Cyclopentadienyl Tricarbonyl Complexes of (99m)tc Mimicking Chalcone As Potential Single-Photon Emission Computed Tomography Imaging Probes for Β-Amyloid Plaques in Brain.

Bioimaging Agents Based on Redox-Active Transition Metal Complexes